We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
76
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5.42M 0.21%
50,538
+12,301
+32% +$1.42M
RCM
77
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.35M 0.2%
356,851
+154,500
+76% +$2.11M
WST icon
78
West Pharmaceutical
WST
$24.5B
$5.21M 0.2%
+15,036
New +$4.39M
SNN icon
79
Smith & Nephew
SNN
$12.8B
$5.07M 0.19%
181,710
– –
AMED
80
DELISTED
Amedisys
AMED
$5.07M 0.19%
+68,949
New +$5.97M
ADUS icon
81
Addus HomeCare
ADUS
$2.12B
$4.52M 0.17%
42,380
– –
ONC
82
BeOne Medicines Ltd
ONC
$33.5B
$4.52M 0.17%
20,952
– –
CERE
83
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.3M 0.16%
176,483
– –
BCRX icon
84
BioCryst Pharmaceuticals
BCRX
$2.29B
$4.21M 0.16%
504,528
-168,177
-25% -$1.62M
TEVA icon
85
Teva Pharmaceuticals
TEVA
$40.1B
$4.07M 0.15%
459,651
– –
ADPT icon
86
Adaptive Biotechnologies
ADPT
$3.9B
$3.73M 0.14%
422,281
– –
CSII
87
DELISTED
Cardiovascular Systems, Inc.
CSII
$3.47M 0.13%
174,859
– –
KURA icon
88
Kura Oncology
KURA
$841M
$3.46M 0.13%
283,281
– –
MPT
89
Medical Properties Trust
MPT
$2.78B
$3.38M 0.13%
411,743
– –
HR icon
90
Healthcare Realty
HR
$7.02B
$3.38M 0.13%
174,686
– –
DOC icon
91
Healthpeak Properties
DOC
$14.9B
$3.3M 0.13%
150,392
– –
COR icon
92
Cencora
COR
$59.6B
$3.27M 0.12%
20,417
– –
CTLT
93
DELISTED
CATALENT, INC.
CTLT
$3.25M 0.12%
49,406
-76,541
-61% -$4.73M
IBB icon
94
iShares Biotechnology ETF
IBB
$9.39B
$3.17M 0.12%
24,569
– –
MRNS
95
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.15M 0.12%
+456,780
New +$2.86M
IONS icon
96
Ionis Pharmaceuticals
IONS
$9.15B
$3.14M 0.12%
87,840
– –
BPMC
97
DELISTED
Blueprint Medicines
BPMC
$3.05M 0.12%
67,710
– –
MDGL icon
98
Madrigal Pharmaceuticals
MDGL
$11.7B
$3.02M 0.12%
+12,481
New +$3.4M
CRBU icon
99
Caribou Biosciences
CRBU
$156M
$3.01M 0.11%
567,147
– –
XENE icon
100
Xenon Pharmaceuticals
XENE
$6.19B
$3M 0.11%
83,714
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.